Volume 23, Number 9—September 2017
CME ACTIVITY - Research
Epidemiology of Salmonella enterica Serotype Dublin Infections among Humans, United States, 1968–2013
R. Reid Harvey1, Cindy R. Friedman, Stacy M. Crim, Michael Judd, Kelly A. Barrett, Beth Tolar, Jason P. Folster, Patricia M. Griffin, and Allison C. Brown
Table 2
Antimicrobial drug resistance in Salmonella enterica serotype Dublin and other Salmonella, United States, 1996–2013*
| Resistance pattern | Salmonella Dublin, no. (%), n = 102 | Other Salmonella, no. (%), n = 33,415 |
|---|---|---|
| Pansusceptible | 42 (41) | 26,552 (79) |
| Resistant to >1 class | 60 (59) | 6,863 (21) |
| Resistant to >3 classes | 56 (55) | 4,013 (12) |
| Resistant to >5 classes | 47 (46) | 2,374 (7) |
| Resistant to >7 classes | 32 (31) | 601 (2) |
| Resistant to at least ACSSuT† | 42 (41) | 2,156 (6) |
| Resistant to at least ACSSuTAuCx‡ | 29 (28) | 581 (2) |
| Resistant to ceftriaxone | 32 (31) | 947 (3) |
| Resistant to nalidixic acid | 6 (6) | 643 (2) |
| Resistant to nalidixic acid and ceftriaxone | 4 (4) | 39 (0.1) |
*Data from the National Antimicrobial Resistance Monitoring System. p<0.01 for all.
†Resistant to ampicillin, chloramphenicol, streptomycin, sulfamethoxazole/sulfisoxazole,and tetracycline.
‡Resistant to ACSSuT, amoxicillin–clavulanic acid, and ceftriaxone.
1Current affiliation: Centers for Disease Control and Prevention, Morgantown, WV, USA.
Page created: August 15, 2017
Page updated: August 15, 2017
Page reviewed: August 15, 2017
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.